Self-Regulatory Organizations; Chicago Mercantile Exchange Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Regarding Acceptance of a New Series of Credit Default Swap Index Product, 18107-18108 [2014-07042]
Download as PDF
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Notices
SECURITIES AND EXCHANGE
COMMISSION
comments on the proposed rule changes
from interested persons.
[Release No. 34–71799; File No. SR–CME–
2014–09]
I. Self-Regulatory Organization’s
Statement of the Terms of Substance of
the Proposed Rule Changes
Self-Regulatory Organizations;
Chicago Mercantile Exchange Inc.;
Notice of Filing and Immediate
Effectiveness of Proposed Rule
Change Regarding Acceptance of a
New Series of Credit Default Swap
Index Product
CME is filing proposed rule changes
that are limited to its business as a
derivatives clearing organization. More
specifically, the proposed rule changes
involve CME’s acceptance of a new
credit default swap index product
series.
March 25, 2014.
II. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Changes
Pursuant to Section 19(b)(1) of the
Securities Exchange Act of 1934
(‘‘Exchange Act’’ or ‘‘Act’’),1 and Rule
19b–4 thereunder,2 notice is hereby
given that on March 14, 2014, Chicago
Mercantile Exchange Inc. (‘‘CME’’) filed
with the Securities and Exchange
Commission (‘‘Commission’’) the
proposed rule changes described in
Items I and II below, which Items have
been primarily prepared by CME. CME
filed the proposal pursuant to Section
19(b)(3)(A)(iii) of the Act 3 and Rule
19b–4(f)(4)(ii) 4 thereunder so that the
proposal was effective upon filing with
the Commission. The Commission is
publishing this notice to solicit
In its filing with the Commission,
CME included statements concerning
the purpose and basis for the proposed
rule changes and discussed any
comments it received on the proposed
rule changes. The text of these
statements may be examined at the
places specified in Item IV below. CME
has prepared summaries, set forth in
sections A, B, and C below, of the most
significant aspects of such statements.
18107
A. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Changes
CME is registered as a DCO with the
Commodity Futures Trading
Commission and offers clearing services
for many different futures and swaps
products, including certain credit
default swap index products. Currently,
CME offers clearing of the Markit CDX
North American Investment Grade
Index Series 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20 and 21. CME also offers
clearing of the Markit CDX North
American High Yield Index Series 11,
12, 13, 14, 15, 16, 17, 18, 19, 20 and 21.
The proposed rule changes would
expand CME’s Markit CDX North
American Investment Grade (‘‘CDX IG’’)
Index and Markit CDX North American
High Yield (‘‘CDX HY’’) Index product
offerings by incorporating the upcoming
Series 22 for both sets of index
products.
In addition to the changes to expand
CME’s CDX offering, CME also proposes
to remove from the current list of
accepted CDX indices certain products
whose termination dates have passed.
These products are set forth in the
following table:
Series
Termination date
(scheduled
termination date)
CDX North American Investment Grade (CDX.NA.IG) ....................................................................................
CDX North American Investment Grade (CDX.NA.IG) ....................................................................................
CDX North American High Yield (CDX.NA.HY) ...............................................................................................
tkelley on DSK3SPTVN1PROD with NOTICES
CDX Index
11
15
11
20 Dec 2013.
20 Dec 2013.
20 Dec 2013.
Although these changes will be
effective on filing, CME plans to
operationalize the proposed changes as
follows: CDX IG 22 will become
available for clearing on March 20,
2014; CDX HY 22 will become available
for clearing on March 27, 2014; the
product deletions will be effective
immediately.
The changes that are described in this
filing are limited to CME’s business as
a DCO clearing products under the
exclusive jurisdiction of the CFTC and
do not materially impact CME’s
security-based swap clearing business in
any way. CME notes that it has also
certified the proposed rule changes that
are the subject of this filing to its
primary regulator, the Commodity
Futures Trading Commission (‘‘CFTC’’),
in a separate filing, CME Submission
14–066.
1 15
2 17
U.S.C. 78s(b)(1).
CFR 240.19b–4.
VerDate Mar<15>2010
18:10 Mar 28, 2014
CME believes the proposed rule
changes are consistent with the
requirements of the Exchange Act
including Section 17A of the Exchange
Act.5 The proposed rule changes would
expand CME’s CDX IG and CDX HY
product offerings by incorporating the
upcoming Series 22 for both sets of
index products and would therefore
provide investors with an expanded
range of derivatives products for
clearing (and would also remove certain
products whose termination dates have
passed). As such, the proposed changes
are designed to promote the prompt and
accurate clearance and settlement of
securities transactions and, to the extent
applicable, derivatives agreements,
contracts, and transactions, to assure the
safeguarding of securities and funds
which are in the custody or control of
the clearing agency or for which it is
responsible, and, in general, to protect
3 15
4 17
Jkt 232001
PO 00000
U.S.C. 78s(b)(3)(A)(iii).
CFR 240.19b–4(f)(4)(ii).
Frm 00104
Fmt 4703
Sfmt 4703
investors and the public interest
consistent with Section 17A(b)(3)(F) of
the Exchange Act.6
Furthermore, the proposed changes
are limited in their effect to swaps
products offered under CME’s authority
to act as a DCO. These products are
under the exclusive jurisdiction of the
CFTC. As such, the proposed CME
changes are limited to CME’s activities
as a DCO clearing swaps that are not
security-based swaps; CME notes that
the policies of the CFTC with respect to
administering the Commodity Exchange
Act are comparable to a number of the
policies underlying the Exchange Act,
such as promoting market transparency
for over-the-counter derivatives markets,
promoting the prompt and accurate
clearance of transactions and protecting
investors and the public interest.
Because the proposed changes are
limited in their effect to swaps products
5 15
6 15
E:\FR\FM\31MRN1.SGM
U.S.C. 78q–1.
U.S.C. 78q–1(b)(3)(F).
31MRN1
18108
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Notices
offered under CME’s authority to act as
a DCO, the proposed changes are
properly classified as effecting a change
in an existing service of CME that:
(a) primarily affects the clearing
operations of CME with respect to
products that are not securities,
including futures that are not security
futures, and swaps that are not securitybased swaps or mixed swaps; and
(b) does not significantly affect any
securities clearing operations of CME or
any rights or obligations of CME with
respect to securities clearing or persons
using such securities-clearing service.
As such, the changes are therefore
consistent with the requirements of
Section 17A of the Exchange Act 7 and
are properly filed under Section
19(b)(3)(A) 8 and Rule 19b–4(f)(4)(ii) 9
thereunder.
B. Self-Regulatory Organization’s
Statement on Burden on Competition
CME does not believe that the
proposed rule changes will have any
impact, or impose any burden, on
competition. The rule changes simply
facilitate the offering of two new series
of credit default swap index products.
C. Self-Regulatory Organization’s
Statement on Comments on the
Proposed Rule Changes Received From
Members, Participants, or Others
CME has not solicited, and does not
intend to solicit, comments regarding
the proposed rule changes. CME has not
received any unsolicited written
comments from interested parties.
tkelley on DSK3SPTVN1PROD with NOTICES
III. Date of Effectiveness of the
Proposed Rule Changes and Timing for
Commission Action
The foregoing rule changes has
become effective pursuant to Section
19(b)(3)(A) 10 of the Act and Rule 19b–
4(f)(4)(ii) 11 thereunder. At any time
within 60 days of the filing of the
proposed rule changes, the Commission
summarily may temporarily suspend
such rule changes if it appears to the
Commission that such action is
necessary or appropriate in the public
interest, for the protection of investors,
or otherwise in furtherance of the
purposes of the Act.
IV. Solicitation of Comments
Interested persons are invited to
submit written data, views and
arguments concerning the foregoing,
including whether the proposed rule
changes are consistent with the Act.
7 15
U.S.C. 78q–1.
U.S.C. 78s(b)(3)(A).
9 17 CFR 240.19b–4(f)(4)(ii).
10 15 U.S.C. 78s(b)(3)(A).
11 17 CFR 240.19b–4(f)(4)(ii).
18:10 Mar 28, 2014
Electronic Comments
• Use the Commission’s Internet
comment form (https://www.sec.gov/
rules/sro.shtml), or
• Send an email to rule-comments@
sec.gov. Please include File No. SR–
CME–2014–09 on the subject line.
Paper Comments
• Send paper comments in triplicate
to Secretary, Securities and Exchange
Commission, 100 F Street NE.,
Washington, DC 20549–1090.
All submissions should refer to File
Number SR–CME–2014–09. This file
number should be included on the
subject line if email is used. To help the
Commission process and review your
comments more efficiently, please use
only one method. The Commission will
post all comments on the Commission’s
Internet Web site (https://www.sec.gov/
rules/sro.shtml). Copies of the
submission, all subsequent
amendments, all written statements
with respect to the proposed rule
changes that are filed with the
Commission, and all written
communications relating to the
proposed rule changes between the
Commission and any person, other than
those that may be withheld from the
public in accordance with the
provisions of 5 U.S.C. 552, will be
available for Web site viewing and
printing in the Commission’s Public
Reference Room, 100 F Street NE.,
Washington, DC 20549, on official
business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of such
filing also will be available for
inspection and copying at the principal
office of CME and on CME’s Web site at
https://www.cmegroup.com/marketregulation/rule-filings.html.
All comments received will be posted
without change; the Commission does not
edit personal identifying information from
submissions. You should submit only
information that you wish to make available
publicly.
All submissions should refer to File
Number SR–CME–2014–09 and should
be submitted on or before April 21,
2014.
For the Commission, by the Division of
Trading and Markets, pursuant to delegated
authority.12
Kevin M. O’Neill,
Deputy Secretary.
[FR Doc. 2014–07042 Filed 3–28–14; 8:45 am]
8 15
VerDate Mar<15>2010
Comments may be submitted by any of
the following methods:
BILLING CODE 8011–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–71797; File No. SR–NSX–
2014–07]
Self-Regulatory Organizations;
National Stock Exchange, Inc.; Notice
of Filing and Immediate Effectiveness
of Proposed Rule Change To Extend a
Pilot Program Related to Rule 11.19,
Titled ‘‘Clearly Erroneous Executions’’
March 25, 2014.
Pursuant to Section 19(b)(1) of the
Securities Exchange Act of 1934 (the
‘‘Act’’) 1 and Rule 19b–4 thereunder,2
notice is hereby given that on March 24,
2014, National Stock Exchange, Inc.
(‘‘NSX’’ or the ‘‘Exchange’’) filed with
the Securities and Exchange
Commission (‘‘Commission’’) the
proposed rule change, as described in
Items I and II below, which Items have
been prepared by the Exchange. The
Commission is publishing this notice to
solicit comments on the proposed rule
change from interested persons.
I. Self-Regulatory Organization’s
Statement of the Terms of the Substance
of the Proposed Rule Change
The Exchange is proposing to amend
Rule 11.19, titled ‘‘Clearly Erroneous
Executions’’ in order to extend the
operation of a pilot program under
which certain portions of the Rule are
currently operating.
The Exchange has designated this
proposal as non-controversial and
provided the Commission with the
notice required by Rule 19b–4(f)(6)(iii)
under the Act.3
The text of the proposed rule change
is available on the Exchange’s Web site
at https://www.nsx.com, at the principal
office of the Exchange, and at the
Commission’s Public Reference Room.
II. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Change
In its filing with the Commission, the
Exchange included statements
concerning the purpose of and basis for
the proposed rule change and discussed
any comments it received on the
proposed rule change. The text of these
statements may be examined at the
places specified in Item IV below. The
Exchange has prepared summaries, set
forth in sections A, B, and C below, of
the most significant parts of such
statements.
1 15
U.S.C. 78s(b)(1).
CFR 240.19b–4.
3 17 CFR 240.19b–4(f)(6)(iii).
2 17
12 17
Jkt 232001
PO 00000
CFR 200.30–3(a)(12).
Frm 00105
Fmt 4703
Sfmt 4703
E:\FR\FM\31MRN1.SGM
31MRN1
Agencies
[Federal Register Volume 79, Number 61 (Monday, March 31, 2014)]
[Notices]
[Pages 18107-18108]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07042]
[[Page 18107]]
-----------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
[Release No. 34-71799; File No. SR-CME-2014-09]
Self-Regulatory Organizations; Chicago Mercantile Exchange Inc.;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change
Regarding Acceptance of a New Series of Credit Default Swap Index
Product
March 25, 2014.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Exchange Act'' or ``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice
is hereby given that on March 14, 2014, Chicago Mercantile Exchange
Inc. (``CME'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule changes described in Items I and II
below, which Items have been primarily prepared by CME. CME filed the
proposal pursuant to Section 19(b)(3)(A)(iii) of the Act \3\ and Rule
19b-4(f)(4)(ii) \4\ thereunder so that the proposal was effective upon
filing with the Commission. The Commission is publishing this notice to
solicit comments on the proposed rule changes from interested persons.
---------------------------------------------------------------------------
\1\ 15 U.S.C. 78s(b)(1).
\2\ 17 CFR 240.19b-4.
\3\ 15 U.S.C. 78s(b)(3)(A)(iii).
\4\ 17 CFR 240.19b-4(f)(4)(ii).
---------------------------------------------------------------------------
I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Changes
CME is filing proposed rule changes that are limited to its
business as a derivatives clearing organization. More specifically, the
proposed rule changes involve CME's acceptance of a new credit default
swap index product series.
II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Changes
In its filing with the Commission, CME included statements
concerning the purpose and basis for the proposed rule changes and
discussed any comments it received on the proposed rule changes. The
text of these statements may be examined at the places specified in
Item IV below. CME has prepared summaries, set forth in sections A, B,
and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Changes
CME is registered as a DCO with the Commodity Futures Trading
Commission and offers clearing services for many different futures and
swaps products, including certain credit default swap index products.
Currently, CME offers clearing of the Markit CDX North American
Investment Grade Index Series 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20 and 21. CME also offers clearing of the Markit CDX North
American High Yield Index Series 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
and 21.
The proposed rule changes would expand CME's Markit CDX North
American Investment Grade (``CDX IG'') Index and Markit CDX North
American High Yield (``CDX HY'') Index product offerings by
incorporating the upcoming Series 22 for both sets of index products.
In addition to the changes to expand CME's CDX offering, CME also
proposes to remove from the current list of accepted CDX indices
certain products whose termination dates have passed. These products
are set forth in the following table:
------------------------------------------------------------------------
Termination date
CDX Index Series (scheduled termination
date)
------------------------------------------------------------------------
CDX North American Investment 11 20 Dec 2013.
Grade (CDX.NA.IG).
CDX North American Investment 15 20 Dec 2013.
Grade (CDX.NA.IG).
CDX North American High Yield 11 20 Dec 2013.
(CDX.NA.HY).
------------------------------------------------------------------------
Although these changes will be effective on filing, CME plans to
operationalize the proposed changes as follows: CDX IG 22 will become
available for clearing on March 20, 2014; CDX HY 22 will become
available for clearing on March 27, 2014; the product deletions will be
effective immediately.
The changes that are described in this filing are limited to CME's
business as a DCO clearing products under the exclusive jurisdiction of
the CFTC and do not materially impact CME's security-based swap
clearing business in any way. CME notes that it has also certified the
proposed rule changes that are the subject of this filing to its
primary regulator, the Commodity Futures Trading Commission (``CFTC''),
in a separate filing, CME Submission 14-066.
CME believes the proposed rule changes are consistent with the
requirements of the Exchange Act including Section 17A of the Exchange
Act.\5\ The proposed rule changes would expand CME's CDX IG and CDX HY
product offerings by incorporating the upcoming Series 22 for both sets
of index products and would therefore provide investors with an
expanded range of derivatives products for clearing (and would also
remove certain products whose termination dates have passed). As such,
the proposed changes are designed to promote the prompt and accurate
clearance and settlement of securities transactions and, to the extent
applicable, derivatives agreements, contracts, and transactions, to
assure the safeguarding of securities and funds which are in the
custody or control of the clearing agency or for which it is
responsible, and, in general, to protect investors and the public
interest consistent with Section 17A(b)(3)(F) of the Exchange Act.\6\
---------------------------------------------------------------------------
\5\ 15 U.S.C. 78q-1.
\6\ 15 U.S.C. 78q-1(b)(3)(F).
---------------------------------------------------------------------------
Furthermore, the proposed changes are limited in their effect to
swaps products offered under CME's authority to act as a DCO. These
products are under the exclusive jurisdiction of the CFTC. As such, the
proposed CME changes are limited to CME's activities as a DCO clearing
swaps that are not security-based swaps; CME notes that the policies of
the CFTC with respect to administering the Commodity Exchange Act are
comparable to a number of the policies underlying the Exchange Act,
such as promoting market transparency for over-the-counter derivatives
markets, promoting the prompt and accurate clearance of transactions
and protecting investors and the public interest.
Because the proposed changes are limited in their effect to swaps
products
[[Page 18108]]
offered under CME's authority to act as a DCO, the proposed changes are
properly classified as effecting a change in an existing service of CME
that:
(a) primarily affects the clearing operations of CME with respect
to products that are not securities, including futures that are not
security futures, and swaps that are not security-based swaps or mixed
swaps; and
(b) does not significantly affect any securities clearing
operations of CME or any rights or obligations of CME with respect to
securities clearing or persons using such securities-clearing service.
As such, the changes are therefore consistent with the requirements
of Section 17A of the Exchange Act \7\ and are properly filed under
Section 19(b)(3)(A) \8\ and Rule 19b-4(f)(4)(ii) \9\ thereunder.
---------------------------------------------------------------------------
\7\ 15 U.S.C. 78q-1.
\8\ 15 U.S.C. 78s(b)(3)(A).
\9\ 17 CFR 240.19b-4(f)(4)(ii).
---------------------------------------------------------------------------
B. Self-Regulatory Organization's Statement on Burden on Competition
CME does not believe that the proposed rule changes will have any
impact, or impose any burden, on competition. The rule changes simply
facilitate the offering of two new series of credit default swap index
products.
C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Changes Received From Members, Participants, or Others
CME has not solicited, and does not intend to solicit, comments
regarding the proposed rule changes. CME has not received any
unsolicited written comments from interested parties.
III. Date of Effectiveness of the Proposed Rule Changes and Timing for
Commission Action
The foregoing rule changes has become effective pursuant to Section
19(b)(3)(A) \10\ of the Act and Rule 19b-4(f)(4)(ii) \11\ thereunder.
At any time within 60 days of the filing of the proposed rule changes,
the Commission summarily may temporarily suspend such rule changes if
it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.
---------------------------------------------------------------------------
\10\ 15 U.S.C. 78s(b)(3)(A).
\11\ 17 CFR 240.19b-4(f)(4)(ii).
---------------------------------------------------------------------------
IV. Solicitation of Comments
Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
changes are consistent with the Act. Comments may be submitted by any
of the following methods:
Electronic Comments
Use the Commission's Internet comment form (https://www.sec.gov/rules/sro.shtml), or
Send an email to rule-comments@sec.gov. Please include
File No. SR-CME-2014-09 on the subject line.
Paper Comments
Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE., Washington, DC 20549-1090.
All submissions should refer to File Number SR-CME-2014-09. This file
number should be included on the subject line if email is used. To help
the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (https://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule changes that are
filed with the Commission, and all written communications relating to
the proposed rule changes between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street NE.,
Washington, DC 20549, on official business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of such filing also will be available
for inspection and copying at the principal office of CME and on CME's
Web site at https://www.cmegroup.com/market-regulation/rule-filings.html.
All comments received will be posted without change; the
Commission does not edit personal identifying information from
submissions. You should submit only information that you wish to
make available publicly.
All submissions should refer to File Number SR-CME-2014-09 and
should be submitted on or before April 21, 2014.
For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\12\
---------------------------------------------------------------------------
\12\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------
Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2014-07042 Filed 3-28-14; 8:45 am]
BILLING CODE 8011-01-P